Core Viewpoint - The company, Sealy Medical Technology Group Co., Ltd., has received a corrective order from the Hubei Regulatory Bureau of the China Securities Regulatory Commission, requiring it to rectify issues related to the mismanagement of raised funds and non-compliance with disclosure regulations [1][2]. Group 1: Company Issues and Rectification - The company failed to repay temporarily used raised funds of 82 million yuan, 374 million yuan, and 50 million yuan on the specified dates, leading to discrepancies in disclosed information regarding the usage period of these funds [2][3]. - The company's actions violated regulatory requirements concerning the management and use of raised funds and information disclosure [3]. Group 2: Rectification Measures - The company is actively seeking funds through various means, including enhancing accounts receivable collection, expanding business scale, and selling equity assets, to repay the raised funds as soon as possible [4]. - The company will strengthen financial planning to ensure that the raised funds are only used for operations related to its main business and will enhance fund management to resolve repayment issues promptly [5]. - The company has organized training for its board members and management to improve compliance awareness regarding the management and use of raised funds, and it will actively disclose the progress of fund repayment [6][7]. Group 3: Completion Timeline and Responsibilities - The company aims to fully repay the outstanding raised funds by the end of June 2025 [7]. - The responsibility for rectification lies with the chairman, general manager, financial director, board secretary, finance department, and securities department [8]. Group 4: Summary of Rectification - The company will enhance communication with regulatory authorities and implement corrective measures to protect investor rights, improve internal control systems, and ensure high-quality sustainable development [9].